CD28 - CD28 molecule Gene
Species: Felis catus
Gene Type: protein coding
Gene ID: 493802
CD28 Products (1)
| mRNA | Protein | Name |
|---|---|---|
| NM_001009844.1 | NP_001009844.1 | T-cell-specific surface glycoprotein CD28 precursor |
CD28 Protein Structure
Ig
Ig: cl11960 (21 - 137)
Ig
Ig: cd00096 (36 - 40)
Ig
Ig: cd00096 (52 - 56)
Ig
Ig: cd00096 (95 - 99)
Ig
Ig: cd00096 (109 - 114)
Ig
Ig: cd00096 (127 - 131)
- 0
- 100
- 200
- 221 a.a.
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
T-cell-specific surface glycoprotein CD28 |
|
Related Agents
- Clinical Phase
- Pre-clinical Phase
Clinical Phase
Bioactive Molecules
(2)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase
|
|---|---|---|---|---|
| HY-P1698 | Reltecimod | Antagonist | 98.62% | Phase 3 |
| HY-P1698B | Reltecimod TFA | Chemical | 99.78% | Phase 3 |
Inhibitory Antibodies
(13)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase
|
|---|---|---|---|---|
| HY-P9986 | Tiragolumab | Inhibitor | 99.04% | Phase 3 |
| HY-P99293 | Galiximab | Inhibitor | 99.23% | Phase 3 |
| HY-P99961 | Tifcemalimab | Inhibitor | 96.02% | Phase 3 |
| HY-P99302 | Lulizumab | Inhibitor | ≥95.0% | Phase 2 |
| HY-P990587 | FR104 | Inhibitor | 97.26% | Phase 2 |
| HY-P99420 | Acazicolcept | Antagonist | 99.27% | Phase 2 |
| HY-P990773 | Venanprubart | Inhibitor | 98.00% | Phase 2 |
| HY-P99431 | KY-1044 | 99.51% | Phase 2 | |
| HY-P990079 | Renvistobart | Inhibitor | 99.95% | Phase 2 |
| HY-P99893 | Rozibafusp alfa | Inhibitor | 96.98% | Phase 2 |
| HY-P990752 | Nezastomig | / | Phase 2 | |
| HY-P991176 | RG-6333 | Agonist | 98.05% | Phase 1 |
| HY-P991183 | SAR-442257 | Inhibitor | ≥99.0% | Phase 1 |
Pre-clinical Phase
Bioactive Molecules
(13)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-122822 | GSK699 | Activator | 98.80% | Unkown |
| HY-102090 | B7/CD28 interaction inhibitor 1 | 99.81% | Unkown | |
| HY-100891 | CD80-IN-3 | 98.02% | Unkown | |
| HY-19486 | UR-1505 | Inhibitor | 99.97% | Unkown |
| HY-179648 | CD28-IN-2 | Inhibitor | / | Unkown |
| HY-176265 | DDS5 | Inhibitor | / | Unkown |
| HY-175780 | CD28-IN-1 | Inhibitor | / | Unkown |
| HY-162810 | ICOS-IN-1 | / | Unkown | |
| HY-169819 | Calcium influx inducer compound 634 | Activator | / | Unkown |
| HY-N10446 | Maydispenoid B | / | Unkown | |
| HY-N10445 | Maydispenoid A | / | Unkown | |
| HY-181507 | CD28-IN-3 | Inhibitor | / | Unkown |
| HY-168384 | M04 | / | Unkown |
Bioactive MoleculesInhibitory Antibodies
(19)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-P9975 | Theralizumab | Agonist | 99.46% | Unkown |
| HY-P99123 | Anti-Mouse CD28 Antibody (37.51) | 95.00% | Unkown | |
| HY-P990865 | Anti-CD28 Antibody (9.3) | Inhibitor | 99% | Unkown |
| HY-P990136 | Anti-Monkey/Human CD28 Antibody (CD28.2) | Inhibitor | 95.00% | Unkown |
| HY-P991907 | Anti-CD80 Antibody (TKMF5) | 96.92% | Unkown | |
| HY-P990298 | Anti-Mouse BTLA/CD272 Antibody (6A6) | Inhibitor | 95.00% | Unkown |
| HY-P992125 | Radanstobart | Inhibitor | 99.12% | Unkown |
| HY-P990237 | Anti-Mouse ICOS Antibody (7E.17G9) | Inhibitor | 98% | Unkown |
| HY-P991038 | Zadoprubart | 99% | Unkown | |
| HY-P992182 | ANB032 | Agonist | / | Unkown |
| HY-P992196 | Anti-Canine CD28 Antibody (1C6) | Inhibitor | / | Unkown |
| HY-P991835 | Anti-Mouse BTLA/CD272 Antibody (PJ196) | Inhibitor | / | Unkown |
| HY-P991833 | Anti-Mouse BTLA/CD272 Antibody (PK18.6) | Inhibitor | / | Unkown |
| HY-P990128 | Anti-Rat CD80/B7-1 Antibody (3H5) | Inhibitor | / | Unkown |
| HY-P990137 | Anti-Rat CD28 Antibody (JJ319) | Inhibitor | / | Unkown |
| HY-P990819 | Anti-Rat CD28 Antibody (JJ316) | Inhibitor | / | Unkown |
| HY-P990803 | Anti-Mouse CD28 Antibody (PV-1) | Inhibitor | 96.63% | Unkown |
| HY-P99123A | Anti-Mouse CD28 (LALA-PG) Antibody (D665) | Inhibitor | / | Unkown |
| HY-P990793 | Anti-Mouse CD28 Antibody (D665) | Inhibitor | / | Unkown |
Compound Screening Libraries
Virtual Screening
Customize Your Library
Drug Screening Service